These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Survival analysis of patients with duodenal gastrointestinal stromal tumors.
    Author: Miki Y, Kurokawa Y, Hirao M, Fujitani K, Iwasa Y, Mano M, Nakamori S, Tsujinaka T.
    Journal: J Clin Gastroenterol; 2010 Feb; 44(2):97-101. PubMed ID: 19809358.
    Abstract:
    GOALS: To evaluate the survival characteristics of patients with duodenal gastrointestinal stromal tumors (GISTs). BACKGROUND: GISTs represent the most common mesenchymal neoplasms. However, duodenal GISTs are relatively rare, and few studies have been performed with a focus on duodenal GISTs. STUDY: We collected the data of 41 GIST patients including 7 duodenal cases. Clinicopathologic findings and recurrence-free survival (RFS) of duodenal GIST patients were analyzed. RESULTS: The proportion of having any symptoms was 86% in duodenum, 32% in stomach, and 56% in other GISTs (P=0.034), and the most common symptoms of duodenal GISTs were melena and anemia. The 2-year RFS rates were 51.4% in duodenal GISTs, 78.4% in stomach GISTs, and 100% in other GISTs, and duodenal GISTs showed poorer RFS than nonduodenal GISTs (hazard ratio, 5.1; log-rank P=0.019). Particularly, in low-risk and intermediate-risk group, the hazard ratio of recurrence was 12.3 (log-rank P=0.010). Multivariate Cox analysis showed symptom (P=0.007), mitotic index (P=0.011), and tumor location (P=0.043) were significant prognostic factors of recurrence. CONCLUSIONS: RFS of duodenal GISTs was worse than nonduodenal GISTs.
    [Abstract] [Full Text] [Related] [New Search]